Background: Influenza is an important cause of morbidity and mortality among older adults. Even so, effectiveness of influenza vaccine for older adults has been reported to be lower than for younger adults, and the impact of frailty on vaccine effectiveness (VE) and outcomes is uncertain. We aimed to study VE against influenza hospitalization in older adults, focusing on the impact of frailty. Methods: We report VE of trivalent influenza vaccine (TIV) in people ≥65 years of age hospitalized during the 2011-2012 influenza season using a multicenter, prospective, test-negative case-control design. A validated frailty index (FI) was used to measure frailty. Results: Three hundred twenty cases and 564 controls (mean age, 80.6 and 78.7 years, respectively) were enrolled. Cases had higher baseline frailty than controls (P = .006). In the fully adjusted model, VE against influenza hospitalization was 58.0% (95% confidence interval [CI], 34.2%-73.2%). The contribution of frailty was important; adjusting for frailty alone yielded a VE estimate of 58.7% (95% CI, 36.2%-73.2%). VE was 77.6% among nonfrail older adults and declined as frailty increased. Conclusions: Despite commonly held views that VE is poor in older adults, we found that TIV provided good protection against influenza hospitalization in older adults who were not frail, though VE diminished as frailty increased. Clinical Trials Registration: NCT01517191.
Background: Influenza is an important cause of morbidity and mortality among older adults. Even so, effectiveness of influenza vaccine for older adults has been reported to be lower than for younger adults, and the impact of frailty on vaccine effectiveness (VE) and outcomes is uncertain. We aimed to study VE against influenza hospitalization in older adults, focusing on the impact of frailty. Methods: We report VE of trivalent influenza vaccine (TIV) in people ≥65 years of age hospitalized during the 2011-2012 influenza season using a multicenter, prospective, test-negative case-control design. A validated frailty index (FI) was used to measure frailty. Results: Three hundred twenty cases and 564 controls (mean age, 80.6 and 78.7 years, respectively) were enrolled. Cases had higher baseline frailty than controls (P = .006). In the fully adjusted model, VE against influenza hospitalization was 58.0% (95% confidence interval [CI], 34.2%-73.2%). The contribution of frailty was important; adjusting for frailty alone yielded a VE estimate of 58.7% (95% CI, 36.2%-73.2%). VE was 77.6% among nonfrail older adults and declined as frailty increased. Conclusions: Despite commonly held views that VE is poor in older adults, we found that TIV provided good protection against influenza hospitalization in older adults who were not frail, though VE diminished as frailty increased. Clinical Trials Registration: NCT01517191.
Authors: H Keipp Talbot; Yuwei Zhu; Qingxia Chen; John V Williams; Mark G Thompson; Marie R Griffin Journal: Clin Infect Dis Date: 2013-02-28 Impact factor: 9.079
Authors: Danuta M Skowronski; Gaston De Serres; Jim Dickinson; Martin Petric; Annie Mak; Kevin Fonseca; Trijntje L Kwindt; Tracy Chan; Nathalie Bastien; Hugues Charest; Yan Li Journal: J Infect Dis Date: 2009-01-15 Impact factor: 5.226
Authors: Christopher A Czaja; Lisa Miller; Nisha Alden; Heidi L Wald; Charisse Nitura Cummings; Melissa A Rolfes; Evan J Anderson; Nancy M Bennett; Laurie M Billing; Shua J Chai; Seth Eckel; Robert Mansmann; Melissa McMahon; Maya L Monroe; Alison Muse; Ilene Risk; William Schaffner; Ann R Thomas; Kimberly Yousey-Hindes; Shikha Garg; Rachel K Herlihy Journal: Open Forum Infect Dis Date: 2019-07-01 Impact factor: 3.835
Authors: Jill M Ferdinands; Manjusha Gaglani; Emily T Martin; Don Middleton; Arnold S Monto; Kempapura Murthy; Fernanda P Silveira; H Keipp Talbot; Richard Zimmerman; Elif Alyanak; Courtney Strickland; Sarah Spencer; Alicia M Fry Journal: J Infect Dis Date: 2019-09-13 Impact factor: 5.226
Authors: Melissa K Andrew; Susan K Bowles; Graham Pawelec; Laura Haynes; George A Kuchel; Shelly A McNeil; Janet E McElhaney Journal: Drugs Aging Date: 2019-01 Impact factor: 3.923
Authors: Caitlin Lees; Judith Godin; Janet E McElhaney; Shelly A McNeil; Mark Loeb; Todd F Hatchette; Jason LeBlanc; William Bowie; Guy Boivin; Allison McGeer; André Poirier; Jeff Powis; Makeda Semret; Duncan Webster; Melissa K Andrew Journal: J Infect Dis Date: 2020-07-06 Impact factor: 5.226
Authors: Olga Theou; Alexandra M van der Valk; Judith Godin; Melissa K Andrew; Janet E McElhaney; Shelly A McNeil; Kenneth Rockwood Journal: J Gerontol A Biol Sci Med Sci Date: 2020-09-25 Impact factor: 6.053
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Niharika A Duggal; Grace Niemiro; Stephen D R Harridge; Richard J Simpson; Janet M Lord Journal: Nat Rev Immunol Date: 2019-09 Impact factor: 53.106